Compass Therapeutics appoints Richard S. Lindahl to Board and Audit Committee chair

Compass Therapeutics, Inc.

Richard S. Lindahl appointed as Class III director effective April 21, 2023; term expires at 2023 annual meeting.
Also appointed chairman of Audit Committee; qualifies as independent director and audit committee financial expert.
Compensation: $45,000 cash retainer, $10,000 additional for Audit Committee chair; 50,000 share option award vesting monthly over four years.
No family relationships or reportable transactions with the Company or its officers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard S. Lindahl

Class III Director

CMPX · Compass Therapeutics, Inc.

Effective: 2023-04-21
Filed: April 24, 2023, 7:59 PM ET

On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard S. Lindahl was appointed as Class III Director at Compass Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On April 21, 2023, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) approved the appointment of a new director to its Board: Richard S. Lindahl, MBA, who is currently the executive vice president, chief financial officer, and treasurer of Emergent BioSolutions, Inc.

View on SEC.gov

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-002480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.